The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS ...

The mRNA-based vaccines that turned the tide of the COVID-19 pandemic currently account for almost all the value of the mRNA vaccine/therapeutic market. Indeed, the vaccine-led response to the ...

Ottawa, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The global mRNA quality monitoring market size is calculated at USD 1.37 billion in 2025 and is expected to reach around USD 2.5 billion by 2034, growing at a ...

SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...

STONY BROOK, NY / ACCESSWIRE / August 23, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the ...

Innovation Center of NanoMedicine (Center Director: Prof. Kazunori Kataoka) has announced that Prof. Satoshi Uchida (Principal Research Scientist), who is also Associated Professor of the Kyoto ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of an advanced animal mRNA vaccine platform to accelerate the development ...

Moderna (MRNA) provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 ...